


37. (amended) The composition of Claim 1 [or 2] wherein T<sub>1</sub> is selected from the group consisting of:



B7 39. (amended) The composition of Claim 1 [or 2] wherein J<sub>1a</sub> is H.

B8 42. (amended) The composition of Claim 1 [or 2] wherein W<sub>6</sub> is secondary or tertiary alkyl containing 4 to 12 carbon atoms which W<sub>6</sub> is unsubstituted or substituted with NO<sub>2</sub>, N<sub>3</sub>, F, Br, Cl, OR<sub>1</sub> or SR<sub>1</sub>.

B9 44. (amended) The composition of Claim 1 [or 2] wherein W<sub>6</sub> is -(CH<sub>2</sub>)<sub>m1</sub>CH(R<sub>1</sub>)<sub>a</sub>W<sub>7</sub> wherein W<sub>7</sub> is an alkyl of 1 to 4 carbon atoms substituted with 0 to 3 R<sub>3</sub>, a is 0 or 1, and when a is 0 then W<sub>7</sub> is joined to CH by a double bond.

B10 47. (amended) The composition of Claim 1 [or 2] wherein W<sub>6</sub> is (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>CH-, (CH<sub>3</sub>CH<sub>2</sub>)(CH<sub>3</sub>)(H)C-, (CH<sub>3</sub>)<sub>2</sub>(H)C-, (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-, CH<sub>3</sub>(CH<sub>2</sub>)<sub>4</sub>-, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>-, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>-, (CH<sub>3</sub>CH<sub>2</sub>)(CH<sub>3</sub>)<sub>2</sub>C-, (CH<sub>3</sub>CH<sub>2</sub>)(CH<sub>3</sub>CH<sub>2</sub>)(H)C-, (CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>)(CH<sub>3</sub>CH<sub>2</sub>)(H)C-, (CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>)(CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>)(H)C-, (PhCH<sub>2</sub>CH<sub>2</sub>)(CH<sub>3</sub>CH<sub>2</sub>)(H)C-, (PhCH<sub>2</sub>CH<sub>2</sub>)(PhCH<sub>2</sub>CH<sub>2</sub>)(H)C-, (PhCH<sub>2</sub>)(CH<sub>3</sub>CH<sub>2</sub>)(H)C-, (PhCH<sub>2</sub>)(PhCH<sub>2</sub>)(H)C-, cyclohexyl- or cyclopentyl-.

B11 52. (amended) The composition of Claim 1 [or 2] wherein E<sub>1</sub> is -COOH, or a carboxyl ester or carboxylamide that is hydrolyzable *in vivo* to -COOH.

53. (amended) The composition of Claim 1 [or 2] further comprising a pharmaceutically-acceptable carrier.

#### Remarks

Applicants request reconsideration of the present application under 35 U.S.C. §111 in view of the amendment above and the discussion that follows.

The Amendment

Applicants have deleted Claims 29, 38, and 50-51 as directed toward non-elected inventions. In addition, Claims 10-14, 18, 20, 25, 26, 30, 31, 34-37, 39, 42, 44, 47, 52 and 53 have been amended to eliminate dependence from non-elected claims.

The Office Action

The Office has rejected Claims 10-27, 29-31, 34-39, 42-47 and 50-53 under 35 U.S.C. § 112, second paragraph, as being directed toward non-elected subject matter. Specifically, the Office has rejected Claims 10-14, 18, 20, 25, 26, 29-31, 34-39, 42, 44, 47, 50, 52 and 53 as depending from non-elected Claim 2 and the remaining claims to the extent that they incorporate terminology from non-elected inventions.

Applicants have amended the claims to eliminate all reference to non-elected inventions. Thus, this rejection is rendered moot.


Conclusion

Applicants have demonstrated that Claims 1, 3-5, 10-28, 30-37, 39-49, 52, 53 and 55 meet the requirements of 35 U.S.C. §112, second paragraph. Expedited allowance of this case is respectfully requested.

Request for a Telephonic Interview

If the Examiner deems it useful, Applicants request, at the Examiner's convenience, a telephonic interview with Mark Bosse at (650) 572-6569 for the purpose of expediting the allowance of the present Application.

Respectfully submitted,



Mark L. Bosse, Reg. No. 35,071  
Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City, CA 94404  
Telephone: (650) 572-6569  
Facsimile: (650) 573-4899  
Dated: 07/27/98